Purinergic signalling: Its unpopular beginning, its acceptance and its exciting future

BioEssays

Volumn 34, Issue 3, 2012, Pages 218-225

  Burnstock, Geoffrey ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

ATP release and breakdown; Neurodegenerative diseases; P1; P2X; P2Y; Pain; Purinergic neuropathology; Purinoceptors

Indexed keywords

4 AMINOBUTYRIC ACID; ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATE; CALCITONIN GENE RELATED PEPTIDE; DOPAMINE; GLUTAMIC ACID; NEUROPEPTIDE Y; NITRIC OXIDE; NORADRENALIN; PURINERGIC P2 RECEPTOR; PURINERGIC P2X1 RECEPTOR; PURINERGIC P2X2 RECEPTOR; PURINERGIC P2X3 RECEPTOR; PURINERGIC P2X4 RECEPTOR; PURINERGIC P2X5 RECEPTOR; PURINERGIC P2X6 RECEPTOR; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y2 RECEPTOR; PURINERGIC P2Y4 RECEPTOR; PURINERGIC P2Y6 RECEPTOR; PURINERGIC RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE;

CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; DEGENERATIVE DISEASE; ENZYME RELEASE; EXCITATORY JUNCTION POTENTIAL; HUMAN; NEUROTRANSMISSION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; ANIMALS; HUMANS; ION CHANNELS; NERVOUS SYSTEM; NEURODEGENERATIVE DISEASES; NEUROTRANSMITTER AGENTS; PERIPHERAL NERVOUS SYSTEM; PURINERGIC P2 RECEPTOR AGONISTS; PURINES; PYRIMIDINES; RECEPTORS, PURINERGIC; RECEPTORS, PURINERGIC P2X; SYNAPTIC TRANSMISSION;

EID: 84857045446     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201100130     Document Type: Review

References (112)

1. Burnstock G, Campbell G, Bennett M, Holman ME. 1963. Inhibition of the smooth muscle of the taenia coli. Nature 200: 581- 2.
2. Burnstock G. 2004. A moment of excitement. Living History Series. The discovery of non-adrenergic, non-cholinergic neurotransmission. Physiol News 56: 7- 9.
3. Burnstock G, Campbell G, Bennett M, Holman ME. 1964. Innervation of the guinea-pig taenia coli: Are there intrinsic inhibitory nerves which are distinct from sympathetic nerves? Int J Neuropharmacol 3: 163- 6.
4. Burnstock G, Campbell G, Rand MJ. 1966. The inhibitory innervation of the taenia of the guinea-pig caecum. J Physiol 182: 504- 26.
5. Drury AN, Szent-Györgyi A. 1929. The physiological activity of adenine compounds with special reference to their action upon the mammalian heart. J Physiol (Lond) 68: 213- 37.
6. Feldberg W, Hebb C. 1948. The stimulating action of phosphate compounds on the perfused superior cervical ganglion of the cat. J Physiol 107: 210- 21.
7. Holton P. 1959. The liberation of adenosine triphosphate on antidromic stimulation of sensory nerves. J Physiol 145: 494- 504.
8. Burnstock G, Campbell G, Satchell D, Smythe A. 1970. Evidence that adenosine triphosphate or a related nucleotide is the transmitter substance released by non-adrenergic inhibitory nerves in the gut. Br J Pharmacol 40: 668- 88.
9. Burnstock G. 1972. Purinergic nerves. Pharmacol Rev 24: 509- 81.
10. 3H]Adenosine triphosphate: release during stimulation of enteric nerves. Science 173: 337- 9.
11. Burnstock G. 1976. Do some nerve cells release more than one transmitter? Neuroscience 1: 239- 48.
12. Burnstock G, Holman ME. 1961. The transmission of excitation from autonomic nerve to smooth muscle. J Physiol 155: 115- 33.
13. Kasakov L, Burnstock G. 1983. The use of the slowly degradable analog, α, β-methylene ATP, to produce desensitisation of the P2-purinoceptor: effect on non-adrenergic, non-cholinergic responses of the guinea-pig urinary bladder. Eur J Pharmacol 86: 291- 4.
14. Sneddon P, Burnstock G. 1984. Inhibition of excitatory junction potentials in guinea-pig vas deferens by α, β-methylene-ATP: further evidence for ATP and noradrenaline as cotransmitters. Eur J Pharmacol 100: 85- 90.
15. Burnstock G. 2007. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 87: 659- 797.
16. Evans RJ, Derkach V, Surprenant A. 1992. ATP mediates fast synaptic transmission in mammalian neurons. Nature 357: 503- 5.
17. Silinsky EM, Gerzanich V, Vanner SM. 1992. ATP mediates excitatory synaptic transmission in mammalian neurones. Br J Pharmacol 106: 762- 3.
18. Edwards FA, Gibb AJ, Colquhoun D. 1992. ATP receptor-mediated synaptic currents in the central nervous system. Nature 359: 144- 7.
19. Burnstock G. 1978. A basis for distinguishing two types of purinergic receptor. In Straub RW, Bolis L, eds; Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach. New York: Raven Press. p. 107- 18.
20. Burnstock G, Kennedy C. 1985. Is there a basis for distinguishing two types of P2-purinoceptor? Gen Pharmacol 16: 433- 40.
21. Lustig KD, Shiau AK, Brake AJ, Julius D. 1993. Expression cloning of an ATP receptor from mouse neuroblastoma cells. Proc Natl Acad Sci USA 90: 5113- 7.
22. Webb TE, Simon J, Krishek BJ, Bateson AN, et al. 1993. Cloning and functional expression of a brain G-protein-coupled ATP receptor. FEBS Lett 324: 219- 25.
23. Brake AJ, Wagenbach MJ, Julius D. 1994. New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor. Nature 371: 519- 23.
24. Valera S, Hussy N, Evans RJ, Adani N, et al. 1994. A new class of ligand-gated ion channel defined by P2X receptor for extracellular ATP. Nature 371: 516- 9.
25. 2Y purinoceptors? Pharmacol Ther 64: 445- 75.
26. Ralevic V, Burnstock G. 1998. Receptors for purines and pyrimidines. Pharmacol Rev 50: 413- 92.
27. Burnstock G. 2007. Purine and pyrimidine receptors. Cell Mol Life Sci 64: 1471- 83.
28. 3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels. EMBO J 17: 3016- 28.
29. Burnstock G, Verkhratsky A, Fredholm B. 2011. Adenosine and ATP receptors in the brain. Curr Top Med Chem 11: 973- 1011.
30. Burnstock G, Knight GE. 2004. Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 240: 31- 304.
31. Inoue K. 2008. Purinergic systems in microglia. Cell Mol Life Sci 65: 3074- 80.
32. 4 ion channel in the closed state. Nature 460: 592- 8.
33. Jacobson KA, Boeynaems JM. 2010. P2Y nucleotide receptors: promise of therapeutic applications. Drug Discov Today 15: 570- 8.
34. Gunosewoyo H, Kassiou M. 2010. P2X purinergic receptor ligands: recently patented compounds. Expert Opin Ther Pat 20: 625- 46.
35. Press NJ, Fozard JR. 2010. Progress towards novel adenosine receptor therapeutics gleaned from the recent patent literature. Expert Opin Ther Pat 20: 987- 1005.
36. Gu BJ, Zhang W, Worthington RA, Sluyter R, et al. 2001. A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J Biol Chem 276: 11135- 42.
37. 7 receptor function via distinct mechanisms revealed by single-nucleotide polymorphisms. J Biol Chem 286: 8176- 87.
38. Burnstock G, Kennedy C. 2011. P2X receptors in health and disease. In Jacobson KA, Linden A, eds; Purine and Pyrimidine Receptor Pharmacology. Burlington: Academic Press. p. 333- 72.
39. Jiang S, Liu A, Duan H, Soo J, et al. 2011. Labeling and tracking P2 purinergic receptors in living cells using ATP-conjugated quantum dots. Adv Funct Mater 21: 2776- 80.
40. Burnstock G, Verkhratsky A. 2009. Evolutionary origins of the purinergic signalling system. Acta Physiol 195: 415- 47.
41. Fountain SJ, Burnstock G. 2009. An evolutionary history of P2X receptors. Purinergic Signal 5: 269- 72.
42. Galimov EM. 2009. Concept of sustained ordering and an ATP-related mechanism of life's origin. Int J Mol Sci 10: 2019- 30.
43. Hoyle CH. 2011. Evolution of neuronal signalling: transmitters and receptors. Auton Neurosci 165: 28- 53.
44. Agboh KC, Webb TE, Evans RJ, Ennion SJ. 2004. Functional characterization of a P2X receptor from Schistosoma mansoni. J Biol Chem 279: 41650- 7.
45. Fountain SJ, Parkinson K, Young MT, Cao L, et al. 2007. An intracellular P2X receptor required for osmoregulation in Dictyostelium discoideum. Nature 448: 200- 3.
46. Fountain SJ, Cao L, Young MT, North RA. 2008. Permeation properties of a P2X receptor in the green algae Ostreococcus tauri. J Biol Chem 283: 15122- 6.
47. Demidchik V, Nichols C, Oliynyk M, Dark A, et al. 2003. Is ATP a signaling agent in plants? Plant Physiol 133: 456- 61.
48. Clark G, Roux SJ. 2009. Extracellular nucleotides: ancient signaling molecules. Plant Sci 177: 239- 44.
49. Kim SY, Sivaguru M, Stacey G. 2006. Extracellular ATP in plants. Visualization, localization, and analysis of physiological significance in growth and signaling. Plant Physiol 142: 984- 92.
50. Clark G, Fraley D, Steinebrunner I, Cervantes A, et al. 2011. Extracellular nucleotides and apyrases regulate stomatal aperture in Arabidopsis. Plant Physiol 156: 1740- 53.
51. Chivasa S, Murphy AM, Hamilton JM, Lindsey K, et al. 2009. Extracellular ATP is a regulator of pathogen defence in plants. Plant J 60: 436- 48.
52. Sreedharan S, Shaik JH, Olszewski PK, Levine AS, et al. 2010. Glutamate, aspartate and nucleotide transporters in the SLC17 family form four main phylogenetic clusters: evolution and tissue expression. BMC Genomics 11: 17.
53. Abbracchio MP, Burnstock G. 1998. Purinergic signalling: pathophysiological roles. Jpn J Pharmacol 78: 113- 45.
54. Burnstock G, Verkhratsky A. 2010. Long-term (trophic) purinergic signalling: purinoceptors control cell proliferation, differentiation and death. Cell Death Dis 1: e9.
55. Burnstock G. 2002. Purinergic signalling and vascular cell proliferation and death. Arterioscler Thromb Vasc 22: 364- 73.
56. Erlinge D, Burnstock G. 2008. P2 receptors in cardiovascular physiology and disease. Purinergic Signal 4: 1- 20.
57. Massé K, Bhamra S, Eason R, Dale N, et al. 2007. Purine-mediated signalling triggers eye development. Nature 449: 1058- 62.
58. Trujillo CA, Schwindt TT, Martins AH, Alves JM, et al. 2009. Novel perspectives of neural stem cell differentiation: from neurotransmitters to therapeutics. Cytometry A 75: 38- 53.
59. Grimm I, Messemer N, Stanke M, Gachet C, et al. 2009. Coordinate pathways for nucleotide and EGF signaling in cultured adult neural progenitor cells. J Cell Sci 122: 2524- 33.
60. Burnstock G, Ulrich H. 2011. Purinergic signalling in embryonic and stem cell development. Cell Mol Life Sci 68: 1369- 94.
61. Delic J, Zimmermann H. 2010. Nucleotides affect neurogenesis and dopaminergic differentiation of mouse fetal midbrain-derived neural precursor cells. Purinergic Signal 6: 417- 28.
62. Bodin P, Burnstock G. 2001. Purinergic signalling: ATP release. Neurochem Res 26: 959- 69.
63. Lazarowski ER, Sesma JI, Seminario-Vidal L, Kreda SM. 2011. Molecular mechanisms of purine and pyrimidine nucleotide release. Adv Pharmacol 61: 221- 61.
64. Sawada K, Echigo N, Juge N, Miyaji T, et al. 2008. Identification of a vesicular nucleotide transporter. Proc Natl Acad Sci USA 105: 5683- 6.
65. Fields RD. 2011. Imaging single photons and intrinsic optical signals for studies of vesicular and non-vesicular ATP release from axons. Front Neuroanat 5: 32.
66. Zimmermann H, Mishra SK, Shukla V, Langer D, et al. 2007. Ecto-nucleotidases, molecular properties and functional impact. An R Acad Nac Farm 73: 537- 66.
67. Yegutkin GG. 2008. Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta 1783: 673- 94.
68. Deaglio S, Robson SC. 2011. Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. In: Jacobson KA, Linden J, eds; Advances in Pharmacology. Pharmacology of Purine and Pyrimidine Receptors. San Diego: Academic Press. p. 301- 32.
69. Burnstock G, Krügel U, Abbracchio MP, Illes P. 2011. Purinergic signalling: from normal behaviour to pathological brain function. Prog Neurobiol 95: 229- 74.
70. Burnstock G. 2006. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 58: 58- 86.
71. Bogdanov YD, Dale L, King BF, Whittock N, et al. 1997. Early expression of a novel nucleotide receptor in the neural plate of Xenopus embryos. J Biol Chem 272: 12583- 90.
72. 1 suggests a role for nucleotide signalling in development of the chick embryo. Dev Dyn 214: 152- 8.
73. Ryten M, Hoebertz A, Burnstock G. 2001. Sequential expression of three receptor subtypes for extracellular ATP in developing rat skeletal muscle. Dev Dyn 221: 331- 41.
74. Cheung K-K, Chan WY, Burnstock G. 2005. Expression of P2X receptors during rat brain development and their inhibitory role on motor axon outgrowth in neural tube explant cultures. Neuroscience 133: 937- 45.
75. Tew EMM, Anderson PN, Burnstock G. 1992. Implantation of the myenteric plexus into the corpus striatum of adult rats: survival of the neurones and glia and interactions with host brain. Restor Neurol Neurosci 4: 311- 21.
76. Höpker VH, Saffrey MJ, Burnstock G. 1996. Neurite outgrowth of striatal neurons in vitro: involvement of purines in the growth promoting effect of myenteric plexus explants. Int J Dev Neurosci 14: 439- 51.
77. Burnstock G, Cocks T, Kasakov L, Wong HK. 1978. Direct evidence for ATP release from non-adrenergic, non-cholinergic ("purinergic") nerves in the guinea-pig taenia coli and bladder. Eur J Pharmacol 49: 145- 9.
78. Burnstock G. 2001. Purinergic signalling in lower urinary tract. In Abbracchio MP, Williams M, eds; Handbook of Experimental Pharmacology, Volume 151/I. Purinergic and Pyrimidinergic Signalling I - Molecular, Nervous and Urinogenitary System Function. Berlin: Springer-Verlag. p. 423- 515.
79. Vidal M, Hicks PE, Langer SZ. 1986. Differential effects of α, β-methylene ATP on responses to nerve stimulation in SHR and WKY tail arteries. Naunyn Schmiedebergs Arch Pharmacol 332: 384- 90.
80. Chen CC, Akopian AN, Sivilotti L, Colquhoun D, et al. 1995. A P2X purinoceptor expressed by a subset of sensory neurons. Nature 377: 428- 31.
81. 3 purinoceptors in sensory neurons: effects of axotomy and glial-derived neurotrophic factor. Mol Cell Neurosci 12: 256- 68.
82. Burnstock G. 1996. A unifying purinergic hypothesis for the initiation of pain. Lancet 347: 1604- 5.
83. Burnstock G. 1999. Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction. J Anat 194: 335- 42.
84. 3 knockout mice reveal a major sensory role for urothelially released ATP. J Neurosci 21: 5670- 7.
85. Rong W, Burnstock G. 2004. Activation of ureter nociceptors by exogenous and endogenous ATP in guinea pig. Neuropharmacology 47: 1093- 101.
86. Wynn G, Burnstock G. 2006. Adenosine 5′-triphosphate and its relationship with other mediators that activate pelvic afferent neurons in the rat colorectum. Purinergic Signal 2: 517- 26.
87. 3-deficient mice. Nature 407: 1011- 5.
88. Inoue K. 2007. P2 receptors and chronic pain. Purinergic Signal 3: 135- 44.
89. Burnstock G. 2009. Purinergic receptors and pain. Curr Pharm Design 15: 1717- 35.
90. Fields D, Burnstock G. 2006. Purinergic signalling in neuron-glial interactions. Nat Rev Neurosci 7: 423- 36.
91. Burnstock G. 2008. Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov 7: 575- 90.
92. Boisson D, Burnstock G. 2010. Eds: Special Issue. Purinergic signalling in epilepsy. Open Neurosci J 4: 23- 113.
93. Burnstock G. 2011. Therapeutic potential of purinergic signalling for diseases of the urinary tract. BJU Int 107: 192- 204.
94. Ryten M, Yang SY, Dunn PM, Goldspink G, et al. 2004. Purinoceptor expression in regenerating skeletal muscle in the mdx mouse model of muscular dystrophy and in satellite cell cultures. FASEB J 18: 1404- 6.
95. Burnstock G. 2008. Commentary. Purinergic receptors as future targets for treatment of functional GI disorders. Gut 57: 1193- 4.
96. Burnstock G, Arnett TR. 2006. Edited Monograph: Nucleotides and Regulation of Bone Cell Function. Boca Raton: Taylor & Francis Group.
97. Orriss IR, Burnstock G, Arnett TR. 2010. Purinergic signalling and bone remodelling. Curr Opin Pharmacol 10: 322- 30.
98. Bailey MA, Shirley DG, King BF, Burnstock G, et al. 2007. Extracellular nucleotides and renal function. In Alpern RJ, Herbert SCG, eds; The Kidney: Physiology and Pathophysiology. San Diego: Elsevier. p. 425- 43.
99. 7-deficiency ameliorates accelerated nephrotoxic nephritis in mice. J Am Soc Nephrol 20: 1275- 81.
100. Calvert RC, Khan MA, Thompson CS, Mikhailidis DP, et al. 2008. A functional study of purinergic signalling in the normal and pathological rabbit corpus cavernosum. BJU Int 101: 1043- 7.
101. Gür S, Kadowitz PJ, Abdel-Mageed AS, Kendirci M, et al. 2009. Management of erectile function by purinergic P2 receptors in diabetic rat. J Urol 181: 2382.
102. Séror C, Melki MT, Subra F, Raza SQ, et al. 2011. Extracellular ATP acts on P2Y2 purinergic receptors to facilitate HIV-1 infection. J Exp Med 208: 1823- 34.
103. White N, Burnstock G. 2006. P2 receptors and cancer. Trends Pharmacol Sci 27: 211- 7.
104. Shabbir M, Thompson CS, Jarmulowicz M, Mikhailidis DP, et al. 2008. Effect of extracellular ATP on the growth of hormone refractory prostate cancer in vivo. BJU Int 102: 108- 12.
105. Shabbir M, Burnstock G. 2009. Purinergic receptor-mediated effects of adenosine 5′-triphosphate in urological malignant diseases. Int J Urol 16: 143- 50.
106. White N, Knight GE, Butler PEM, Burnstock G. 2009. An in vivo model of melanoma: treatment with ATP. Purinergic Signal 5: 327- 33.
107. Stagg J, Smyth MJ. 2010. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29: 5346- 58.
108. Rapaport E. 1983. Treatment of human tumor cells with ADP or ATP yields arrest of growth in the S phase of the cell cycle. J Cell Physiol 114: 279- 83.
109. Yegutkin GG, Marttila-Ichihara F, Karikoski M, Niemela J, et al. 2011. Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. Eur J Immunol 41: 1231- 41.
110. Hansen RR, Nielsen CK, Nasser A, Thomsen SI, et al. 2011. P2X7 receptor-deficient mice are susceptible to bone cancer pain. Pain 152: 1766- 76.
111. Burnstock G. 2009. Acupuncture: a novel hypothesis for the involvement of purinergic signalling. Med Hypotheses 73: 470- 2.
112. Burnstock G. 2003. Introduction: ATP and its metabolites as potent extracellular agonists. In Schwiebert EM, ed; Current Topics in Membranes, Vol 54. Purinergic Receptors and Signalling. San Diego: Academic Press. p. 1- 27.